|
Amgen's Repatha (Evolocumab) Reduces MACE Events In FOURIER Trial
|
3
|
Resverlogix Corp.
|
Feb 02, 2017 05:28PM
|
|
Re: Keystone and Dialysis Conference
|
2
|
Resverlogix Corp.
|
Feb 02, 2017 05:30PM
|
|
Re: Esperion
|
6
|
Resverlogix Corp.
|
Feb 03, 2017 10:55AM
|
|
Re: Esperion
|
7
|
Resverlogix Corp.
|
Feb 03, 2017 12:41PM
|
|
Re: Rheumatoid Arthritis
|
4
|
Resverlogix Corp.
|
Feb 04, 2017 12:14AM
|
|
Re: Any thoughts on ESPR's climb?
|
1
|
Resverlogix Corp.
|
Feb 08, 2017 08:53AM
|
|
Re: Futility analysis
|
6
|
Resverlogix Corp.
|
Feb 08, 2017 10:48AM
|
|
Re: Gasoline
|
3
|
Zenith Epigenetics
|
Feb 09, 2017 02:15PM
|
|
Resverlogix's 2017 Outlook Video
|
4
|
Resverlogix Corp.
|
Feb 09, 2017 04:41PM
|
|
Re: Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
|
5
|
Resverlogix Corp.
|
Feb 13, 2017 10:41AM
|
|
Zenith BIO CEO & Investor Conference 2017 Slides
|
3
|
Zenith Epigenetics
|
Feb 14, 2017 12:17PM
|
|
Resverlogix BIO CEO & Investor Conference 2017 Slides
|
2
|
Resverlogix Corp.
|
Feb 14, 2017 02:02PM
|
|
Re: Resverlogix BIO CEO & Investor Conference 2017 Slides
|
2
|
Resverlogix Corp.
|
Feb 14, 2017 02:08PM
|
|
Re: Zenith BIO CEO & Investor Conference 2017 Slides
|
2
|
Zenith Epigenetics
|
Feb 14, 2017 06:39PM
|
|
biOasis: Valuing the Licensing Opportunities
|
|
BIOASIS TECHNOLOGIES INC
|
Feb 15, 2017 08:45AM
|
|
Re: Resverlogix BIO CEO & Investor Conference 2017 Slides
|
2
|
Resverlogix Corp.
|
Feb 15, 2017 11:46AM
|
|
Re: Resverlogix BIO CEO & Investor Conference 2017 Slides
|
1
|
Resverlogix Corp.
|
Feb 15, 2017 01:49PM
|
|
Armagen reports early positive Phase II data for AGT-181
|
|
BIOASIS TECHNOLOGIES INC
|
Feb 17, 2017 11:49AM
|
|
Re: Article in Nature - An epigenetics gold rush: new controls for gene expression
|
2
|
Resverlogix Corp.
|
Feb 23, 2017 10:04AM
|
|
Re: Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
|
7
|
Resverlogix Corp.
|
Feb 23, 2017 10:12AM
|
